Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Dhruvanshu Parmar | Researchclopedia

Back to researchers

Dhruvanshu Parmar

Ruhr University Bochum ORCID

81

Works

1,362

Citations

17

h-index

22

i10-index

Research Topics

Particle physics theoretical and experimental studies Quantum Chromodynamics and Particle Interactions Liver Disease Diagnosis and Treatment

Affiliations

Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals1997–1999

University of Ferrara2025–2025

General Motors (India)2024–2024

Zydus Pharmaceuticals (United States)2021–2025

Istituto Nazionale di Fisica Nucleare, Sezione di Ferrara2025–2025

Top Works

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

Samer Gawrieh,Mazen Noureddin,et al.

2021343 citations

High-Energy Particle Collisions Research

Peroxisome Proliferator-Activated Receptors

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

Taufik Momin,Kevinkumar Kansagra,et al.

2021180 citations

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Upendra Kaul,Dhruvanshu Parmar,et al.

2019127 citations

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis

Mohammad Shadab Siddiqui,Michael O. Idowu,et al.

202085 citations

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

Raj Vuppalanchi,Stephen H. Caldwell,et al.

202170 citations

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study

Dhruvanshu Parmar,Kevinkumar Kansagra,et al.

201964 citations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

Dhruvanshu Parmar,Kevinkumar Kansagra,et al.

202263 citations

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

Manjunath Krishnappa,Kishor Patil,et al.

202046 citations

A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG)

Kevinkumar Kansagra,Dhruvanshu Parmar,et al.

202045 citations